GlassScriptPhysician profile
Ann R Abraham
NPI 1447795182
$3,213.04
in general payments reported to CMS, 2019-2025
23 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.75 · 2022: $239 · 2023: $964 · 2024: $807 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,874.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $412.71 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Novo Nordisk INC | $391.46 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Alkermes, INC. | $335.50 | 2021-2025 | Aristada, Vivitrol, Lybalvi |
| Indivior INC. | $330.00 | 2022-2025 | Sublocade |
| Neurocrine Biosciences, INC. | $301.12 | 2023-2025 | Ingrezza |
| Lilly USA, LLC | $259.90 | 2023 | Mounjaro |
| Braeburn INC. | $227.05 | 2024-2025 | Brixadi |
| Teva Pharmaceuticals USA, INC. | $183.15 | 2023-2025 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.67 | 2021-2025 | Caplyta |
| Exact Sciences Corporation | $106.67 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $93.79 | 2023 | Repatha, Otezla |
| Gilead Sciences, INC. | $91.74 | 2022 | |
| Abbvie INC. | $83.21 | 2023-2024 | Mavyret |
| Otsuka America Pharmaceutical, INC. | $56.43 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Vanda Pharmaceuticals INC. | $34.73 | 2024-2025 | Fanapt |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $33.37 | 2024-2025 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $31.27 | 2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $25.00 | 2023 | Vaxelis, Zostavax, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $24.89 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.68 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.78 | 2022 | |
| Pfizer INC. | $14.32 | 2023 | |
| Dexcom, INC. | $13.60 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.